Premium
Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide ( IDegLira ) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used
Author(s) -
Norwood Paul,
Chen Roger,
Jaeckel Elmar,
Lingvay Ildiko,
Jarlov Henrik,
Lehmann Lucine,
Heller Simon
Publication year - 2017
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12972
Subject(s) - insulin degludec , medicine , insulin glargine , liraglutide , insulin , hypoglycemia , dosing , type 2 diabetes , diabetes mellitus , endocrinology
Aims To re‐analyse, using a series of alternative hypoglycaemia definitions, the data from 2 trials, DUAL I and V , in which the once‐daily, fixed ratio combination of insulin degludec/liraglutide ( IDegLira ) was compared with basal insulin therapy. Material and Methods Post hoc analyses of the DUAL I (patients uncontrolled on oral antidiabetic drugs) and DUAL V (patients uncontrolled on insulin glargine ( IGlar ) U100 ) trials were carried out using different definitions of hypoglycaemia and according to whether treatments were administered in the morning or afternoon. Rates of hypoglycaemia for the definitions of confirmed and A merican D iabetes Association ( ADA )‐documented symptomatic hypoglycaemia were compared according to age, gender and body mass index ( BMI ). Results Although hypoglycaemia rates differed according to the alternative hypoglycaemia definitions, rates were consistently lower with IDegLira vs insulin degludec ( IDeg ) and IGlar U100 . Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal‐confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100 , irrespective of dosing time. The definitions of confirmed and ADA ‐documented symptomatic hypoglycaemia did not have a significant effect on the treatment difference between IDegLira and IDeg , liraglutide or IGlar U100 when further assessed by baseline age, gender and BMI . Conclusions Treatment with IDegLira , vs IDeg and IGlar U100 , resulted in lower rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used. The choice of hypoglycaemia definition did not influence the results of analyses when stratified by age, sex and BMI .